Literature DB >> 11553588

Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae.

L Goetsch1, A Gonzalez, H Plotnicky-Gilquin, J F Haeuw, J P Aubry, A Beck, J Y Bonnefoy, N Corvaïa.   

Abstract

Administration of vaccines by the nasal route has recently proven to be one of the most efficient ways for inducing both mucosal and systemic antibody responses in experimental animals. Our results demonstrate that P40, a well-defined outer membrane protein A from Klebsiella pneumoniae, is indeed a carrier molecule suitable for nasal immunization. Using fragments from the respiratory syncytial virus subgroup A (RSV-A) G protein as antigen models, it has been shown that P40 is able to induce both systemic and mucosal immunity when fused or coupled to a protein or a peptide and administered intranasally (i.n.) to naive or K. pneumoniae-primed mice. Confocal analyses of nasal mucosa-associated lymphoid tissue after i.n. instillation of P40 showed that this molecule is able to cross the nasal epithelium and target CD11c-positive cells likely to be murine dendritic cells or macrophages. More importantly, this targeting of antigen-presenting cells following i.n. immunization with a subunit of the RSV-A molecule in the absence of any mucosal adjuvant results in both upper and lower respiratory tract protection against RSV-A infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553588      PMCID: PMC98779          DOI: 10.1128/IAI.69.10.6434-6444.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Prior immunity to a carrier enhances antibody responses to hCG in recipients of an hCG-carrier conjugate vaccine.

Authors:  S Shah; R Raghupathy; O Singh; G P Talwar; A Sodhi
Journal:  Vaccine       Date:  1999-08-06       Impact factor: 3.641

2.  OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway.

Authors:  P Jeannin; T Renno; L Goetsch; I Miconnet; J P Aubry; Y Delneste; N Herbault; T Baussant; G Magistrelli; C Soulas; P Romero; J C Cerottini; J Y Bonnefoy
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

3.  Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier.

Authors:  L D Lise; D Mazier; M Jolivet; F Audibert; L Chedid; D Schlesinger
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

4.  Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant.

Authors:  M Isaka; Y Yasuda; M Mizokami; S Kozuka; T Taniguchi; K Matano; J Maeyama; K Mizuno; K Morokuma; K Ohkuma; N Goto; K Tochikubo
Journal:  Vaccine       Date:  2001-01-08       Impact factor: 3.641

5.  A filter immuno-plaque assay for the detection of antibody-secreting cells in vitro.

Authors:  S A Möller; C A Borrebaeck
Journal:  J Immunol Methods       Date:  1985-05-23       Impact factor: 2.303

6.  Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae.

Authors:  I Rauly; L Goetsch; J F Haeuw; C Tardieux; T Baussant; J Y Bonnefoy; N Corvaia
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

7.  Carrier-priming leads to hapten-specific suppression.

Authors:  L A Herzenberg; T Tokuhisa; L A Herzenberg
Journal:  Nature       Date:  1980-06-26       Impact factor: 49.962

8.  Carrier-induced epitopic suppression, a major issue for future synthetic vaccines.

Authors:  M P Schutze; C Leclerc; M Jolivet; F Audibert; L Chedid
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

Review 9.  Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin.

Authors:  B D Spangler
Journal:  Microbiol Rev       Date:  1992-12

10.  Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses.

Authors:  L A Herzenberg; T Tokuhisa
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  8 in total

1.  Nasal vaccination induces protective immunity without immunopathology.

Authors:  T Hussell; I R Humphreys
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

2.  Protective efficacy of DNA vaccines encoding outer membrane protein A and OmpK36 of Klebsiella pneumoniae in mice.

Authors:  Prathiba Kurupati; N P Ramachandran; Chit Laa Poh
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

3.  Progress towards the development of Klebsiella vaccines.

Authors:  Myeongjin Choi; Sharon M Tennant; Raphael Simon; Alan S Cross
Journal:  Expert Rev Vaccines       Date:  2019-06-28       Impact factor: 5.217

Review 4.  Adjuvants for allergy vaccines.

Authors:  Philippe Moingeon
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

5.  Identification and characterization of antigens as vaccine candidates against Klebsiella pneumoniae.

Authors:  Urban Lundberg; Beatrice M Senn; Wolfgang Schüler; Andreas Meinke; Markus Hanner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

6.  Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.

Authors:  Hesham F Nawar; Sergio Arce; Michael W Russell; Terry D Connell
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

Review 7.  Recent updates in COVID-19 with emphasis on inhalation therapeutics: Nanostructured and targeting systems.

Authors:  Ahmed A H Abdellatif; Hesham M Tawfeek; Ahmed Abdelfattah; Gaber El-Saber Batiha; Helal F Hetta
Journal:  J Drug Deliv Sci Technol       Date:  2021-02-19       Impact factor: 3.981

8.  Identification of B- and T-cell epitopes of BB, a carrier protein derived from the G protein of Streptococcus strain G148.

Authors:  Liliane Goetsch; Jean Francois Haeuw; Thierry Champion; Christine Lacheny; Thien N'Guyen; Alain Beck; Nathalie Corvaia
Journal:  Clin Diagn Lab Immunol       Date:  2003-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.